Turbine, a Budapest, Hungary-based predictive simulation company that is building a platform for interpreting human biology, received an investment from Accenture (NYSE: ACN), through Accenture Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to further extend its capabilities to global biopharma companies that can benefit from its ability to uncover hidden biological insights, with the potential to guide and accelerate key drug development workstreams.
Led by CEO Szabolcs Nagy, Turbine offers a technology, the Simulated Cell™ platform, that uses machine learning to understand how human cells make decisions.
Turbine’s core technology, the Simulated Cell™ platform, utilizes machine learning to understand how human cells make decisions. The platform intricately models molecular interactions within and around cells, enabling virtual experiments in volumes that are nearly impossible to achieve in the physical world and revealing mechanisms that drive diseases and response to therapies.
It is being validated with pharma companies such as AstraZeneca, Ono Pharmaceutical, Cancer Research Horizons, and Bayer. In addition, Turbine has received funding from MSD (Merck & Co, Inc. Rahway NJ, USA) Global Health Innovation Fund, Accel, and MassMutual Ventures, among others.
FinSMEs
17/05/2024